An international study found that finerenone can slow progression of chronic kidney disease and reduce kidney and cardiovascular complication risk in patients who do not have diabetes. The drug was already known in related cardiorenal settings; this work extends evidence to non-diabetic CKD.
Chronic kidney disease raises the chance of kidney failure and heart-related events. Therapies that slow that progression are closely watched by nephrology researchers and clinicians.
The cited health-news summary attributes the benefit finding to the international study and specifies the non-diabetic CKD population. Exact trial size and follow-up length were not included in the one-line source note.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/